CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 72 enrolled
Drug / intervention
0.5% Heavy Bupivacainecombination
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06620614
NCT06620614Phase 1Completed

Comparative Study on Fractionated Versus Bolus Dose of Hyperbaric Bupivacaine in Patients Undergoing Transurethral Resection of Prostate Surgery Under Subarachnoid Block.

National Academy of Medical Sciences, Nepal·interventional·Posted Oct 1, 2024·Updated Oct 8, 2024

In Brief

A Phase 1 clinical trial evaluating 0.5% Heavy Bupivacaine for Prostatic Hyperplasia, Benign. Completed, enrolled 72 participants across 1 site.

Detailed Summary

The goal of this study is to compare the intraoperative hemodynamic status, characteristics of block of fractionated versus single bolus dose of Hyperbaric Bupivacaine in patient undergoing Transurethral Resection of Prostate(TURP) surgery under Subarachnoid block(SAB). Seventy-two patients aged 50 years and above belonging to American Physical status I and II are divided into two study group. Group B will receive Injection 0.5 % hyperbaric bupivacaine 2.5 ml single bolus dose and group F will receive same concentration and volume of hyperbaric bupivacaine with two third dose initially (i.e. 1.6 ml) and remaining one third dose (i.e. 0.9 ml) after 60 seconds at the rate of 0.2ml/sec.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesNepal
Collaborators--

Timeline

Phase 1CompletedFinished
2023202420252026
First PostedOct 1, 2024
Enrollment StartOct 1, 2022
Primary CompletionDec 1, 2022
Study CompletionDec 1, 2023
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 1.8 years ago

Interventions

0.5% Heavy Bupivacainecombination

There are two groups.